Innovation Days
About
Research
Products
Investors
Careers
Agenda
fr
Scientific Presentations
stock information
press releases
events and webcasts
Scientific Presentations
Scientific Publications
corporate presentation
Financial Statements
SEC filings
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
All
2022
2021
16
May 2022
14:22 E.S.T.
Endowing Universal CAR T-cell with Immune-Evasive Properties Using TALEN® -Gene Editing- ASGCT 2022
Download the PDF file
11
Apr 2022
11:16 E.S.T.
UCART20x22: First allogeneic dual CAR T-cell therapy for the treatment of B-cell malignancies - AACR 2022 - PDF abstract
Download the PDF file
10
Apr 2022
16:41 E.S.T.
UCART20x22: First allogeneic dual CAR T-cell therapy for the treatment of B-cell malignancies - AACR 2022 - PDF Poster
Download the PDF file
11
Dec 2021
10:57 E.S.T.
Pre-clinical Development of a Highly Efficient TALEN®- ASH 2021
Download the PDF file
11
Dec 2021
10:55 E.S.T.
Preliminary Results from the Flu/Cy/Alemtuzumab arm of the Phase I BALLI-01 Trial of UCART22- ASH 2021
Download the PDF file
12
Nov 2021
11:45 E.S.T.
Mesothelin (MSLN) Targeting Allogeneic CAR T Cells Engineedred to Overcome Tumor Immunosuppressive Microenvironment- SITC 2021
Download the PDF file
27
Oct 2021
09:18 E.S.T.
Preclinical development of a TALEN-based genome editing in T cells for the treatment of Hyper-IgE-Syndrome - ESGCT 2021
Download the PDF file
27
Oct 2021
09:15 E.S.T.
Preclinical development of a TALEN-based genome editing therapy for RAG1 deficiency - ESGCT 2021
Download the PDF file